KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Research & Development (2016 - 2025)

Exact Sciences (EXAS) has disclosed Research & Development for 16 consecutive years, with $191.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 95.99% to $191.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $523.0 million, a 21.29% increase, with the full-year FY2025 number at $523.0 million, up 21.29% from a year prior.
  • Research & Development was $191.5 million for Q4 2025 at Exact Sciences, up from $117.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $191.5 million in Q4 2025 to a low of $75.4 million in Q3 2021.
  • A 5-year average of $108.0 million and a median of $105.7 million in 2022 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 225.15% in 2021; the steepest drop was 80.18% in 2021.
  • Exact Sciences' Research & Development stood at $88.5 million in 2021, then grew by 7.41% to $95.0 million in 2022, then rose by 21.19% to $115.2 million in 2023, then fell by 15.17% to $97.7 million in 2024, then soared by 95.99% to $191.5 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Research & Development are $191.5 million (Q4 2025), $117.3 million (Q3 2025), and $108.9 million (Q2 2025).